Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Work In Process (2018 - 2025)

TransMedics has reported Work In Process over the past 8 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Work In Process at $2.0 million for Q4 2025, down 38.73% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 38.73% YoY), and the annual figure for FY2025 was $2.0 million, down 38.73%.
  • Work In Process for Q4 2025 was $2.0 million at TransMedics, up from $1.6 million in the prior quarter.
  • Over the last five years, Work In Process for TMDX hit a ceiling of $4.9 million in Q3 2024 and a floor of $1.3 million in Q2 2021.
  • Median Work In Process over the past 5 years was $2.4 million (2022), compared with a mean of $2.7 million.
  • Biggest five-year swings in Work In Process: surged 102.88% in 2023 and later tumbled 66.52% in 2025.
  • TransMedics' Work In Process stood at $1.9 million in 2021, then fell by 2.9% to $1.9 million in 2022, then surged by 102.88% to $3.8 million in 2023, then dropped by 13.98% to $3.3 million in 2024, then plummeted by 38.73% to $2.0 million in 2025.
  • The last three reported values for Work In Process were $2.0 million (Q4 2025), $1.6 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.